Short Summary
Olympus Corporation et al. successfully navigated the institution phase in an IPR against Optimum Imaging Technologies, LLC regarding imaging systems technology. The Board preliminarily found a reasonable likelihood of unpatentability based on multiple grounds of obviousness (103).
Detailed Summary
The Patent Trial and Appeal Board instituted the IPR petition filed by Olympus Corporation et al. against Optimum Imaging Technologies, LLC concerning patent 10873685, which covers imaging systems technology. The Board found that Petitioner demonstrated a reasonable likelihood of showing at least one claim is unpatentable under 103. Key to the institution decision was the Board adopting the plain and ordinary meaning for the term 'database,' rejecting the Patent Owner's argument that it must be updateable. This ruling allows the case to proceed to trial, despite related district court litigation and IPR proceedings.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Olympus Corporation et al. vs Optimum Imaging Technologies LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Taiwan Semiconductor Manufacturing Company Ltd.vsAdvanced Integrated Circuit Process LLC
TSMC’s request for a Director‑review of an inter‑ partes review was denied, leaving Advanced Integrated Circuit Process’s semiconductor process patent intact. The Board affirmed the Director’s discretionary denial based on lack of persuasive justification and potential duplication with district‑court litigation.
Medtronic, Inc.vsMoskowitz Family LLC
Medtronic has filed an IPR petition challenging claim 43 of U.S. Patent 9,005,293, asserting that the claim is anticipated or obvious over prior‑art spinal‑implant references. The petition highlights alleged nondisclosure of key references during prosecution and deficiencies in the patent’s written description.
Par Health, Inc.vsInfoRLife, S.A.
Par Health petitions the PTAB to institute a post‑grant review of U.S. Patent 12,370,153 covering ready‑to‑use ketamine infusion formulations. The petition asserts anticipation by a Biomed data sheet and obviousness over Biomed combined with standard pharmaceutical references and commercial infusion bag literature.
Target CorporationvsHEADWATER RESEARCH LLC
The PTAB issued a Final Written Decision finding all of the challenged claims of Headwater’s ’541 patent unpatentable. Google and its wireless partners successfully argued anticipation and obviousness over the Rao reference and related prior art.
Google LLC et al.vsSoftView LLC
Google has filed an IPR petition seeking cancellation of claims 1‑35 of SoftView’s ’154 patent, asserting obviousness over Zaurus, Pad++, SVG and SVF prior art and arguing that the claims are patentably indistinct from already invalidated claims in related patents.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.